This AOP is licensed under the BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.

AOP: 645

Title

A descriptive phrase which references both the Molecular Initiating Event and Adverse Outcome.It should take the form “MIE leading to AO”. For example, “Aromatase inhibition leading to reproductive dysfunction” where Aromatase inhibition is the MIE and reproductive dysfunction the AO. In cases where the MIE is unknown or undefined, the earliest known KE in the chain (i.e., furthest upstream) should be used in lieu of the MIE and it should be made clear that the stated event is a KE and not the MIE.  More help

Binding and activation of AhR lead to cardiovascular aging

Short name
A name that succinctly summarises the information from the title. This name should not exceed 90 characters. More help
Binding and activation of AhR lead to cardiovascular aging
The current version of the Developer's Handbook will be automatically populated into the Handbook Version field when a new AOP page is created.Authors have the option to switch to a newer (but not older) Handbook version any time thereafter. More help
Handbook Version v2.8

Graphical Representation

A graphical representation of the AOP.This graphic should list all KEs in sequence, including the MIE (if known) and AO, and the pair-wise relationships (links or KERs) between those KEs. More help
Click to download graphical representation template Explore AOP in a Third Party Tool

Authors

The names and affiliations of the individual(s)/organisation(s) that created/developed the AOP. More help

Shiheng Gui

Ruifang Fan

Point of Contact

The user responsible for managing the AOP entry in the AOP-KB and controlling write access to the page by defining the contributors as described in the next section.   More help
Shiheng Gui   (email point of contact)

Contributors

Users with write access to the AOP page.  Entries in this field are controlled by the Point of Contact. More help
  • Shiheng Gui
  • Ruifang Fan

Coaches

This field is used to identify coaches who supported the development of the AOP.Each coach selected must be a registered author. More help

OECD Information Table

Provides users with information concerning how actively the AOP page is being developed and whether it is part of the OECD Workplan and has been reviewed and/or endorsed. OECD Project: Assigned upon acceptance onto OECD workplan. This project ID is managed and updated (if needed) by the OECD. OECD Status: For AOPs included on the OECD workplan, ‘OECD status’ tracks the level of review/endorsement of the AOP . This designation is managed and updated by the OECD. Journal-format Article: The OECD is developing co-operation with Scientific Journals for the review and publication of AOPs, via the signature of a Memorandum of Understanding. When the scientific review of an AOP is conducted by these Journals, the journal review panel will review the content of the Wiki. In addition, the Journal may ask the AOP authors to develop a separate manuscript (i.e. Journal Format Article) using a format determined by the Journal for Journal publication. In that case, the journal review panel will be required to review both the Wiki content and the Journal Format Article. The Journal will publish the AOP reviewed through the Journal Format Article. OECD iLibrary published version: OECD iLibrary is the online library of the OECD. The version of the AOP that is published there has been endorsed by the OECD. The purpose of publication on iLibrary is to provide a stable version over time, i.e. the version which has been reviewed and revised based on the outcome of the review. AOPs are viewed as living documents and may continue to evolve on the AOP-Wiki after their OECD endorsement and publication.   More help
OECD Project # OECD Status Reviewer's Reports Journal-format Article OECD iLibrary Published Version
This AOP was last modified on July 09, 2026 09:44

Revision dates for related pages

Page Revision Date/Time
Aryl hydrocarbon receptor(AhR)activation July 09, 2026 03:41
Increase, Oxidative Stress February 11, 2026 07:05
Increase, DNA damage May 08, 2019 12:28
Increase, Cell cycle arrest July 09, 2026 04:05
Impact on sirtuins-related aging signaling pathway gene expression July 09, 2026 03:52
Disruption, Mitochondrial dysfunction July 09, 2026 04:54
Increase, Myocardial and vascular structural remodeling July 09, 2026 05:00
Increase, Systemic inflammation July 09, 2026 05:02
Increase, Blood pressure elevation July 09, 2026 05:06
Increase, Cardiovascular aging July 09, 2026 05:08
Increase, Telomere attrition July 09, 2026 06:05
AhR activation leads to Increase, Oxidative Stress July 09, 2026 05:09
Increase, Oxidative Stress leads to Impact on sirtuins-related aging signaling pathway gene expression July 09, 2026 07:58
Impact on sirtuins-related aging signaling pathway gene expression leads to Increase, DNA Damage July 09, 2026 05:11
Increase, DNA Damage leads to Cell cycle arrest July 09, 2026 05:12
Cell cycle arrest leads to Increase, Telomere attrition July 09, 2026 08:11
Increase, DNA Damage leads to Mitochondrial dysfunction July 09, 2026 08:13
Increase, Oxidative Stress leads to Systemic inflammation July 09, 2026 08:14
Impact on sirtuins-related aging signaling pathway gene expression leads to Myocardial and vascular structural remodeling July 09, 2026 08:15
Myocardial and vascular structural remodeling leads to Blood pressure elevation July 09, 2026 08:15
Myocardial and vascular structural remodeling leads to Cardiovascular aging July 09, 2026 08:19
Naphthalene July 03, 2026 11:28
Acenaphthene July 09, 2026 06:10
Acenaphthylene July 09, 2026 06:14
Fluorene July 09, 2026 06:14
Phenanthrene November 29, 2016 18:42
Anthracene July 03, 2026 11:29
Fluoranthene July 09, 2026 06:28
Pyrene July 03, 2026 11:30
Chrysene July 03, 2026 11:31
Benzo(b)fluoranthene July 03, 2026 11:22
Benzo(k)fluoranthene November 29, 2016 18:42
Benzo(a)pyrene March 20, 2020 20:17
Benz(a)anthracene July 03, 2026 11:31
Indeno(1,2,3-cd)pyrene July 09, 2026 07:32
Dibenz(a,h)anthracene July 09, 2026 07:32
Benzo(g,h,i)perylene July 09, 2026 07:33

Abstract

A concise and informative summation of the AOP under development that can stand-alone from the AOP page. The aim is to capture the highlights of the AOP and its potential scientific and regulatory relevance. More help

This AOP aims to elucidate the key biological pathways through which polycyclic aromatic hydrocarbons (PAHs) activate the aryl hydrocarbon receptor (AhR) and promote cardiovascular aging. AhR is a ligand-dependent transcription factor that plays a central role in regulating the expression of xenobiotic metabolism and detoxification-related enzymes (such as the CYP family); simultaneously, AhR is expressed in various tissue types including vascular endothelium, and its activation is closely associated with endothelial dysfunction, inflammatory responses, and vascular remodeling processes. As exogenous pollutants, PAHs may cause multi-system damage after entering the organism. In this AOP, the binding and activation of PAHs to AhR is defined as the Molecular Initiating Event (MIE). Subsequently, AhR signaling can directly or indirectly inhibit the expression or activity of SIRT1/SIRT6, serving as Key Event 1 (KE1), and induce DNA damage responses, further leading to upregulation of p16 and p21, accompanied by aging-related changes including enhanced systemic inflammation and oxidative stress, telomere attrition, and mitochondrial dysfunction. The persistent cellular damage described above ultimately drives structural and functional remodeling of the myocardium and vasculature, manifested as increased vascular calcium deposition, elevated blood pressure, and consequently the formation of cardiovascular aging as the Adverse Outcome (AO). We have identified multiple key events in this pathway and delineated the logical relationships between key events; based on this, we have constructed this AOP to describe the molecular mechanisms by which AhR binding and activation lead to cardiovascular aging.

AOP Development Strategy

Context

Used to provide background information for AOP reviewers and users that is considered helpful in understanding the biology underlying the AOP and the motivation for its development.The background should NOT provide an overview of the AOP, its KEs or KERs, which are captured in more detail below. More help

Polycyclic aromatic hydrocarbons (PAHs) refer to hydrocarbon compounds containing two or more benzene rings in their molecular structure, primarily originating from incomplete combustion of organic matter(Zhang, 2017) . PAHs are widely distributed in environmental water, air, soil, and food. Dietary intake, respiration, and dermal contact are the main routes of PAH exposure, characterized by persistence, passivity, and inevitability, increasing cancer risk and causing high incidence of cardiovascular diseases. Numerous population epidemiological studies have shown that PAHs exposure are closely associated with the development of cardiovascular diseases such as hypertension, atherosclerosis, and ischemic heart disease(Curfs et al., 2004; Xu et al., 2021) . Given their widespread environmental distribution and potential toxicity, the United States Environmental Protection Agency (EPA) has listed 16 of them as priority controlled toxic organic pollutants. Therefore, it is necessary to assess the health risks of PAHs based on the AOP (Adverse Outcome Pathway) framework.

Strategy

Provides a description of the approaches to the identification, screening and quality assessment of the data relevant to identification of the key events and key event relationships included in the AOP or AOP network.This information is important as a basis to support the objective/envisaged application of the AOP by the regulatory community and to facilitate the reuse of its components.  Suggested content includes a rationale for and description of the scope and focus of the data search and identification strategy/ies including the nature of preliminary scoping and/or expert input, the overall literature screening strategy and more focused literature surveys to identify additional information (including e.g., key search terms, databases and time period searched, any tools used). More help

Summary of the AOP

This section is for information that describes the overall AOP.The information described in section 1 is entered on the upper portion of an AOP page within the AOP-Wiki. This is where some background information may be provided, the structure of the AOP is described, and the KEs and KERs are listed. More help

Events:

Molecular Initiating Events (MIE)
An MIE is a specialised KE that represents the beginning (point of interaction between a prototypical stressor and the biological system) of an AOP. More help
Key Events (KE)
A measurable event within a specific biological level of organisation. More help
Adverse Outcomes (AO)
An AO is a specialized KE that represents the end (an adverse outcome of regulatory significance) of an AOP. More help
Type Event ID Title Short name
KE 1392 Increase, Oxidative Stress Increase, Oxidative Stress
KE 2431 Impact on sirtuins-related aging signaling pathway gene expression Impact on sirtuins-related aging signaling pathway gene expression
KE 1194 Increase, DNA damage Increase, DNA Damage
KE 2432 Increase, Cell cycle arrest Cell cycle arrest
KE 2439 Increase, Telomere attrition Increase, Telomere attrition
KE 2434 Disruption, Mitochondrial dysfunction Mitochondrial dysfunction
KE 2436 Increase, Systemic inflammation Systemic inflammation
KE 2435 Increase, Myocardial and vascular structural remodeling Myocardial and vascular structural remodeling
KE 2437 Increase, Blood pressure elevation Blood pressure elevation
AO 2438 Increase, Cardiovascular aging Cardiovascular aging

Relationships Between Two Key Events (Including MIEs and AOs)

This table summarizes all of the KERs of the AOP and is populated in the AOP-Wiki as KERs are added to the AOP.Each table entry acts as a link to the individual KER description page. More help

Network View

This network graphic is automatically generated based on the information provided in the MIE(s), KEs, AO(s), KERs and Weight of Evidence (WoE) summary tables. The width of the edges representing the KERs is determined by its WoE confidence level, with thicker lines representing higher degrees of confidence. This network view also shows which KEs are shared with other AOPs. More help

Prototypical Stressors

A structured data field that can be used to identify one or more “prototypical” stressors that act through this AOP. Prototypical stressors are stressors for which responses at multiple key events have been well documented. More help

Life Stage Applicability

The life stage for which the AOP is known to be applicable. More help
Life stage Evidence
During brain development, adulthood and aging High

Taxonomic Applicability

Latin or common names of a species or broader taxonomic grouping (e.g., class, order, family) can be selected.In many cases, individual species identified in these structured fields will be those for which the strongest evidence used in constructing the AOP was available. More help
Term Scientific Term Evidence Link
human Homo sapiens Low NCBI
rat Rattus norvegicus High NCBI

Sex Applicability

The sex for which the AOP is known to be applicable. More help
Sex Evidence
Male High

Overall Assessment of the AOP

Addressess the relevant biological domain of applicability (i.e., in terms of taxa, sex, life stage, etc.) and Weight of Evidence (WoE) for the overall AOP as a basis to consider appropriate regulatory application (e.g., priority setting, testing strategies or risk assessment). More help

As the DNA damage effects of PAHs are widely recognized, previous research has primarily focused on the carcinogenic, teratogenic, and mutagenic effects induced by PAH-mediated DNA damage. However, DNA damage is also an important driving factor in accelerating cellular senescence, and cellular senescence is an important pathway for suppressing cellular malignant transformation; therefore, this Adverse Outcome Pathway (AOP) focuses on the association between PAH exposure and cardiovascular aging. However, current in vivo and in vitro evidence investigating PAH exposure-induced cardiovascular toxic effects remains relatively limited. Moreover, existing in vivo or in vitro studies typically focus on single or a few PAHs, and the exposure doses set are high, making it difficult to reflect the adverse effects of mixed PAHs at environmental doses on the cardiovascular system in the general population. Therefore, low-dose mixed animal exposure, cell experiments, and computer simulation studies are needed to investigate the adverse effects of mixed exposure to 16 priority-controlled PAHs on the cardiovascular system from the perspective of aging.

This AOP takes AhR activation as the initiating event; PAHs can directly activate AhR(Das et al., 2016), then directly or indirectly inhibit the expression of SIRT1/SIRT6 in the cardiovascular system, and induce DNA damage responses, further leading to upregulation of p16 and p21, accompanied by aging-related changes including enhanced systemic inflammation and oxidative stress, telomere attrition, and mitochondrial dysfunction (Bin et al., 2010; Malik and Czajka, 2013) . Experimental results can be obtained from various models, including experimental animals, mice, and cell lines. Among these, in vivo animal experiments, in vitro experiments, and computer simulation evidence can confirm the associations between the Molecular Initiating Event (MIE) and Key Event Relationships (KERs).

Domain of Applicability

Addressess the relevant biological domain(s) of applicability in terms of sex, life-stage, taxa, and other aspects of biological context. More help

In HUVEC cells, studies have found that exposure to low doses (10-100 µM) of naphthalene, fluoranthene, and fluorene can cause Ca²⁺ ion influx, promote eNOS activation, and further lead to increased NO synthesis(Li et al., 2004) . This suggests that the negative regulatory effect between PAH exposure levels and blood pressure may be closely related to PAH-promoted NO synthesis in endothelial cells. Similarly, in HUVEC cells, exposure to environmental doses of mixed 16 priority-controlled PAHs caused inflammatory responses and oxidative stress, and significantly decreased migration and tube formation capabilities(He et al., 2022).

In rat models, after B[a]P exposure, significant increases in systolic blood pressure, diastolic blood pressure, and mean arterial pressure were observed in rats, with significantly decreased maximal acetylcholine-stimulated aortic relaxation responses(Gan et al., 2012) . In mouse models, B[a]P exposure caused systemic inflammation in apolipoprotein-deficient (ApoE⁻/⁻) mice and led to atherosclerosis development; exposure to 16 priority-controlled PAHs promoted atherosclerotic plaque formation in ApoE⁻/⁻ mice by upregulating miR-155 and inhibiting SERPIND1 expression (He et al., 2021) . Additionally, in zebrafish models, exposure to Pyr, B[a]P, and B[k]P all caused cardiac developmental abnormalities (Zhang et al., 2021).

Meanwhile, combining epidemiological surveys and experimental research results, PAH exposure has significant effects on cardiovascular aging, particularly on blood pressure, atherosclerosis formation, cardiac development, and heart rate. Existing studies have found that urinary 1-OHPhe levels in the hypertension group (0.152 µg/g) were significantly higher than those in the non-hypertension group (0.128 µg/g) (Lee et al., 2020) . Another study found that for every 1 µg/mmol increase in urinary 4-OHPhe or total -OHPAHs content, the 10-year risk of atherosclerotic cardiovascular disease (ASCVD) increased by 12.63% or 11.91%, respectively (p < 0.05) (Yin et al., 2017) . Pregnancy and infancy are critical time windows for cardiac development, relatively sensitive to pollutant exposure. Maternal occupational PAH exposure during pregnancy increases the risk of congenital heart defects (CHD) in offspring, and among occupationally PAH-exposed populations, PAH metabolite levels are associated with decreased heart rate, with a dose-response relationship (Deng et al., 2022; Li et al., 2012).

Essentiality of the Key Events

The essentiality of KEs can only be assessed relative to the impact of manipulation of a given KE (e.g., experimentally blocking or exacerbating the event) on the downstream sequence of KEs defined for the AOP. Consequently, evidence supporting essentiality is assembled on the AOP page, rather than on the independent KE pages that are meant to stand-alone as modular units without reference to other KEs in the sequence. The nature of experimental evidence that is relevant to assessing essentiality relates to the impact on downstream KEs and the AO if upstream KEs are prevented or modified. This includes: Direct evidence: directly measured experimental support that blocking or preventing a KE prevents or impacts downstream KEs in the pathway in the expected fashion. Indirect evidence: evidence that modulation or attenuation in the magnitude of impact on a specific KE (increased effect or decreased effect) is associated with corresponding changes (increases or decreases) in the magnitude or frequency of one or more downstream KEs. More help

MIE1: AhR activation

PAHs (such as benzo[a]pyrene) enter cells as ligands and bind to AhR in the cytoplasm, triggering dissociation of AhR from the molecular chaperone complex (HSP90, XAP2, p23), nuclear translocation, and heterodimer formation with ARNT, thereby binding to XRE sequences to initiate target gene transcription. AhR activation not only initiates Phase I metabolic reactions but also lays the foundation for oxidative stress and inflammatory responses.

KE1: Oxidative stress

Oxidative stress refers to the disruption of redox balance in vivo or within cells, resulting in massive production of ROS (including superoxide anion, hydrogen peroxide, and hydroxyl radicals), while simultaneously consuming intracellular antioxidant substances (GSH, SOD, CAT), exceeding the scavenging capacity of the antioxidant defense system.

KE2: Impact on sirtuins-related aging signaling pathway gene expression

Among the sirtuins family, SIRT1 and SIRT6 are known as "longevity genes" and are NAD⁺-dependent deacetylases that play important roles in maintaining mitochondrial function and integrity, DNA damage repair, telomere maintenance, and cardiovascular homeostasis.

KE3: DNA damage

ROS and PAH active metabolites (such as BPDE) directly attack DNA, forming DNA adducts and leading to double-strand breaks or base mutations.

KE4: Cell cycle arrest

Both p16INK4a and p21Cip1 are cell cycle arrest proteins. When DNA damage occurs within cells, cell cycle checkpoints are activated, cell cycle arrest protein expression increases, causing cell cycle stagnation.

KE5: Telomere attrition

Telomeres serve as protective structures at chromosome ends; their attrition (length shortening or structural dysfunction) is caused by ROS-mediated oxidative damage and end replication problems during DNA replication.

KE6: Mitochondrial dysfunction

With increasing age, various adverse factors accumulate within mitochondria, such as mtDNA mutations and changes in mitochondrial dynamics, which can cause mitochondrial dysfunction, increased ROS generation, and further increase mitochondrial membrane permeability, thereby triggering inflammation and cell death. When mtDNAcn is abnormal, mitochondria are facing stress, which is one manifestation of mitochondrial dysfunction.

KE7: Systemic inflammation

An immune process occurring within cardiovascular tissues characterized by immune cell infiltration, inflammatory factor release, tissue damage, and repair responses.

KE8: Myocardial and vascular structural remodeling

Myocardial and vascular structural remodeling includes ventricular hypertrophy, thinning and loose structure of ventricular walls, focal vascular proliferation, and disordered arrangement of vascular smooth muscle, providing structural basis for subsequent blood pressure elevation and vascular calcification.

KE9: Blood pressure elevation

Vascular aging leads to increased vascular stiffness, disordered secretion of vasoactive substances, decreased vascular diastolic regulation capacity, and increased susceptibility to hypertension. Blood pressure elevation is manifested as sustained elevation of arterial systolic or diastolic pressure; hypertension accelerates vascular remodeling and calcification.

Evidence Assessment

Addressess the biological plausibility, empirical support, and quantitative understanding from each KER in an AOP. More help

Essentiality of KE

Definitional Question

High (Strong)

Moderate

Low (Weak)

If the upstream KE is blocked, will the downstream KE and/or AO be prevented?

Direct evidence from specifically designed experimental studies indicating that at least one important KE is essential

Indirect evidence suggesting that sufficient modification of the expected modulating factor would weaken or enhance the KE

No or contradictory experimental evidence proving the essentiality of any KE

KE1: Oxidative stress

Moderate

Extracellular signaling molecules bind and activate AhR, inducing CYP1A1/1B1 expression, metabolizing PAHs, and producing large amounts of ROS.

KE2: Impact on sirtuins-related aging signaling pathway gene expression

High

The AhR/ARNT complex binds to XREs (xenobiotic response elements) in the SIRT1/SIRT6 promoter regions, inhibiting transcription.

KE3: DNA damage

High

SIRT1/SIRT6 participate in DNA repair; reduced expression of both leads to decreased repair efficiency and accumulation of DNA damage. PAHs can directly and competitively bind to DNA strand binding sites in SIRT6, limiting its ability to bind damaged DNA strands, causing decreased DNA damage response capability of SIRT6, and exacerbating DNA damage in the cardiovascular system.

KE4: Cell cycle arrest

High

DNA damage accumulation activates cell cycle checkpoints, cell cycle arrest proteins p16/p21 expression increases, causing stable cell cycle arrest.

KE5: Telomere attrition

High

DNA damage can cause telomere dysfunction, telomere binding protein TRF2 expression is inhibited, and p53 expression is activated, thereby promoting cellular senescence or apoptosis. Telomerase activity is inhibited in senescent cells. The p53/p21 and p16/pRB pathways may synergistically limit telomerase expression. ROS continuously attacks telomere DNA.

KE6: Mitochondrial dysfunction

High

DNA damage can cause mitochondrial dysfunction by inhibiting PGC-1α through p53, reducing mitochondrial biogenesis; increased ROS generation further increases mitochondrial membrane permeability, potentially causing abnormal mtDNAcn.

KE7: Systemic inflammation

Moderate

Chronic inflammation caused by oxidative stress activates pathways such as NF-κB and releases pro-inflammatory cytokines such as TNF-α, causing cardiovascular system aging.

KE8: Myocardial and vascular structural remodeling

High

Decreased SIRT1/SIRT6 expression causes cardiovascular aging and myocardial and vascular remodeling. Inflammatory factors promote myocardial and vascular structural remodeling. Environmental doses of PAHs cause ventricular hypertrophy in rats, while high concentrations of PAH exposure cause thinning of ventricular walls and structural dilation. High concentration PAH exposure causes focal arterial proliferation, disordered smooth muscle arrangement, and increased arterial calcium deposition, causing vascular structural changes.

KE9: Blood pressure elevation

High

Decreased vascular compliance leads to increased peripheral resistance. Increased arterial stiffness leads to elevated systolic pressure and increased pulse pressure difference.

AO: Cardiovascular aging

High

Cardiovascular aging caused by hypertension is usually associated with cardiovascular structural and functional abnormalities; sustained hypertension accelerates increased cardiac afterload, myocardial hypertrophy, and deterioration of vascular lesions.

Known Modulating Factors

Modulating factors (MFs) may alter the shape of the response-response function that describes the quantitative relationship between two KES, thus having an impact on the progression of the pathway or the severity of the AO.The evidence supporting the influence of various modulating factors is assembled within the individual KERs. More help
Modulating Factor (MF) Influence or Outcome KER(s) involved
     

Quantitative Understanding

Optional field to provide quantitative weight of evidence descriptors.  More help

Considerations for Potential Applications of the AOP (optional)

Addressess potential applications of an AOP to support regulatory decision-making.This may include, for example, possible utility for test guideline development or refinement, development of integrated testing and assessment approaches, development of (Q)SARs / or chemical profilers to facilitate the grouping of chemicals for subsequent read-across, screening level hazard assessments or even risk assessment. More help

References

List of the literature that was cited for this AOP. More help

[1]   Bin, P., Leng, S., Cheng, J., Pan, Z.-f., Duan, H., Dai, Y., Li, H.-s., Niu, Y., Liu, Q.-j., Liu, Q.-j., Zheng, Y.-x., 2010. [Association between telomere length and occupational polycyclic aromatic hydrocarbons exposure]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 44 6, 535-538

[2]   Curfs, D.M., Lutgens, E., Gijbels, M.J., Kockx, M.M., Daemen, M.J., van Schooten, F.J., 2004. Chronic exposure to the carcinogenic compound benzo[a]pyrene induces larger and phenotypically different atherosclerotic plaques in ApoE-knockout mice. Am J Pathol 164, 101-108.10.1016/s0002-9440(10)63101-x

[3]   Das, D., Panda, P., Naik, P.P., Mukhopadhyay, S., Sinha, N., Bhutia, S., 2016. Phytotherapeutic approach: a new hope for polycyclic aromatic hydrocarbons induced cellular disorders, autophagic and apoptotic cell death. Toxicology Mechanisms and Methods 27, 1-54.10.1080/15376516.2016.1268228

[4]   Deng, C., Pu, J., Deng, Y., Xie, L., Yu, L., Liu, L., Guo, X., Sandin, S., Liu, H., Dai, L., 2022. Association between maternal smoke exposure and congenital heart defects from a case-control study in China. Sci Rep 12, 14973.10.1038/s41598-022-18909-y

[5]   Gan, T.E., Xiao, S.P., Jiang, Y., Hu, H., Wu, Y.H., Duerksen-Hughes, P.J., Sheng, J.Z., Yang, J., 2012. Effects of Benzo(a)pyrene on the Contractile Function of the Thoracic Aorta of Sprague-dawley Rats. Biomedical and Environmental Sciences 25, 549-556.https://doi.org/10.3967/0895-3988.2012.05.008

[6]   He, J., Pang, Q., Huang, C., Xie, J., Hu, J., Wang, L., Wang, C., Meng, L., Fan, R., 2022. Environmental dose of 16 priority-controlled PAHs mixture induce damages of vascular endothelial cells involved in oxidative stress and inflammation. Toxicology in Vitro 79, 105296.https://doi.org/10.1016/j.tiv.2021.105296

[7]   He, X.N., Xin, J.Y., Zhan, J.L., Wu, F.K., Hou, J., Sun, Z., Wang, J., Zhang, X.L., Bai, Y.C., 2021. Polycyclic aromatic hydrocarbons induce endothelial injury through miR155 to promote atherosclerosis. Environmental and Molecular Mutagenesis 62, 409-421.10.1002/em.22454

[8]   Lee, T.W., Kim, D.H., Ryu, J.Y., 2020. Association between urinary polycyclic aromatic hydrocarbons and hypertension in the Korean population: data from the Second Korean National Environmental Health Survey (2012-2014). Sci Rep 10, 17142.10.1038/s41598-020-74353-w

[9]   Li, C.-H., Lee, C.-C., Juang, H.-A., Kang, J.-J., 2004. Activation and up-regulation of nitric oxide synthase in human umbilical vein endothelial cells by polycyclic aromatic hydrocarbons. Toxicology letters 151, 367-374.10.1016/j.toxlet.2004.03.003

[10] Li, X., Feng, Y., Deng, H., Zhang, W., Kuang, D., Deng, Q., Dai, X., Lin, D., Huang, S., Xin, L., He, Y., Huang, K., He, M., Guo, H., Zhang, X., Wu, T., 2012. The dose-response decrease in heart rate variability: any association with the metabolites of polycyclic aromatic hydrocarbons in coke oven workers? PLoS One 7, e44562.10.1371/journal.pone.0044562

[11] Malik, A.N., Czajka, A., 2013. Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? Mitochondrion 13, 481-492

[12] Xu, C., Liu, Q., Liang, J., Weng, Z., Xu, J., Jiang, Z., Gu, A., 2021. Urinary biomarkers of polycyclic aromatic hydrocarbons and their associations with liver function in adolescents. Environmental Pollution 278, 116842.https://doi.org/10.1016/j.envpol.2021.116842

[13] Yin, W., Hou, J., Xu, T., Cheng, J., Li, P., Wang, L., Zhang, Y., Wang, X., Hu, C., Huang, C., Yu, Z., Yuan, J., 2017. Obesity mediated the association of exposure to polycyclic aromatic hydrocarbon with risk of cardiovascular events. The Science of the total environment 616-617.10.1016/j.scitotenv.2017.10.238

[14] Zhang, S., Ou, K., Huang, J., Fang, L., Wang, C., 2021. In utero exposure to mixed PAHs causes heart mass reduction in adult male mice. Ecotoxicology and environmental safety 225, 112804.10.1016/j.ecoenv.2021.112804

[15] Zhang, Z., 2017. A review of polycyclic aromatic hydrocarbons (PAHs) research progress in China based on CNKI database. AIP Conference Proceedings 1820.10.1063/1.4977385